Announcement PDF ABN 16 165 160 841 +61 (0) 3 9123 1140 | info@ampliatx.com Level 5, 90 William Street, Melbourne VIC 3000 Australia www.ampliatx.com 25 FEBRUARY 2026 ASX RELEASE APPOINTMENT OF CHIEF FINANCIAL OFFICER Melbourne, Australia: Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces the appointment of Mr Hamish George as Chief Financial Officer (CFO) of Amplia effective 25 February 2026. Mr George replaces fellow Bio101 Financial Advisory (Bio101) Director Mr Tim Luscombe, who has held the position since 23 September 2023. Prior to Mr Luscombe holding the position, Mr George was CFO from 1 October 2021. Mr George is a highly experienced Chartered Accountant who holds a Bachelor of Commerce from the University of Melbourne, a Masters Degree in Professional Accounting from RMIT and a Certificate in Governance Practice from the Governance Institute of Australia. Mr George has acted as CFO for numerous life sciences companies including ASX listed companies. Amplia’s CEO and Managing Director, Dr Chris Burns, commented: “We are delighted to welcome Hamish back to Amplia as CFO and we look forward to working with him again. In addition, we want to thank Mr Tim Luscombe for his excellent contributions over the past years.” This ASX announcement was approved and authorised for release by the CEO of Amplia Therapeutics. Investor Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com U.S. Contact: Robert Giordano rjgiordano@ggrouplifesciences.com +1 917 327 3938 Media Contact: H^CK Director, Haley Chartres haley@hck.digital +61 423 139 163 U.S. Media: media@ampliatx.com About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and LinkedIn.